Breast cancer
Open accessThe DOI matches its Crossref record; 324 of the 324 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70–80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with distant organ metastases is considered incurable with currently available therapies. On the molecular level, breast cancer is a heterogeneous disease; molecular features include activation of human epidermal growth factor receptor 2 (HER2, encoded by ERBB2), activation of hormone receptors (oestrogen receptor and progesterone receptor) and/or BRCA mutations. Treatment strategies differ according to molecular subtype. Management of breast cancer is multidisciplinary; it includes locoregional (surgery and radiation therapy) and systemic therapy approaches. Systemic therapies include endocrine therapy for hormone receptor-positive disease, chemotherapy, anti-HER2 therapy for HER2-positive disease, bone stabilizing agents, poly(ADP-ribose) polymerase inhibitors for BRCA mutation carriers and, quite recently, immunotherapy. Future therapeutic concepts in breast cancer aim at individualization of therapy as well as at treatment de-escalation and escalation based on tumour biology and early therapy response. Next to further treatment innovations, equal worldwide access to therapeutic advances remains the global challenge in breast cancer care for the future.Breast cancer is the most frequent malignancy in women worldwide. Patients are managed on the basis of the key molecular and histological features underpinnin…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased counts of tumour-infiltrating lymphocytes (TILs) are prognostic for survival in triple-negative breast cancer (TNBC), making this disease a potential target for immunotherapy.88”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [88]
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Global Cancer Incidence and Mortality Rates and Trends—An Update
Torre, L. A., Siegel, R. L., Ward, E. M., & Jemal, A. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0578 · Cited by 3,692
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Self-citationEarly Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationRisks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
Giuliano, A. E. (2011) · JAMA · doi:10.1001/jama.2011.90 · Cited by 2,942
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., Morris, E., Pisano, E., Schnall, M., Sener, S., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.75 · Cited by 2,637
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X.-S., Bannon, F., Ahn, J. V., Johnson, C. J., Bonaventure, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62038-9 · Cited by 2,614
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8738 · Cited by 2,435
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
EBCTCG (Early Breast Cancer Trialists' Collaborative Group) (2014) · The Lancet · doi:10.1016/s0140-6736(14)60488-8 · Cited by 2,254
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Self-citationA Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer
Veronesi, U., Paganelli, G., Viale, G., Luini, A., Zurrida, S., Galimberti, V., Intra, M., Veronesi, P., Robertson, C., Maisonneuve, P., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa012782 · Cited by 2,210
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force (2016) · Annals of Internal Medicine · doi:10.7326/m15-2886 · Cited by 2,094
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., Brain, E., Causeret, S., DeLorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,994
Self-citationDowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J., Ellis, M., Henry, N. L., Hugh, J. C., Lively, T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr393 · Cited by 1,977
Self-citationHays, R. D., Bjorner, J. B., Revicki, D. A., Spritzer, K. L., & Cella, D. (2009) · Quality of Life Research · doi:10.1007/s11136-009-9496-9 · Cited by 1,957
Krag, D. N., Anderson, S. J., Julian, T. B., Brown, A. M., Harlow, S. P., Costantino, J. P., Ashikaga, T., Weaver, D. L., Mamounas, E. P., Jalovec, L. M., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70207-2 · Cited by 1,920
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Breast cancer statistics, 2017, racial disparity in mortality by state
DeSantis, C. E., Ma, J., Goding Sauer, A., Newman, L. A., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21412 · Cited by 1,879
Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
Whelan, T. J., Pignol, J.-P., Levine, M. N., Julian, J. A., MacKenzie, R., Parpia, S., Shelley, W., Grimard, L., Bowen, J., Lukka, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0906260 · Cited by 1,878
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Ciriello, G., Gatza, M. L., Beck, A. H., Wilkerson, M. D., Rhie, S. K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.033 · Cited by 1,858
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,822
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Oeffinger, K. C., Fontham, E. T. H., Etzioni, R., Herzig, A., Michaelson, J. S., Shih, Y.-C. T., Walter, L. C., Church, T. R., Flowers, C. R., LaMonte, S. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.12783 · Cited by 1,653
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
Self-citationCurrent and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
(2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,520
The benefits and harms of breast cancer screening: an independent review
(2012) · The Lancet · doi:10.1016/s0140-6736(12)61611-0 · Cited by 1,492
Kuehn, T., Bauerfeind, I., Fehm, T., Fleige, B., Hausschild, M., Helms, G., Lebeau, A., Liedtke, C., Minckwitz, G. V., Nekljudova, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70166-9 · Cited by 1,485
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Haviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., Dobbs, H. J., Hopwood, P., Lawton, P. A., Magee, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70386-3 · Cited by 1,470
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703643 · Cited by 1,411
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510764 · Cited by 1,388
Danaei, G., Vander Hoorn, S., Lopez, A. D., Murray, C. J., & Ezzati, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67725-2 · Cited by 1,367
Regional Nodal Irradiation in Early-Stage Breast Cancer
Whelan, T. J., Olivotto, I. A., Parulekar, W. R., Ackerman, I., Chua, B. H., Nabid, A., Vallis, K. A., White, J. R., Rousseau, P., Fortin, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415340 · Cited by 1,294
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citationBreast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0914 · Cited by 1,209
Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx308 · Cited by 1,205
Self-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationThe global burden of women's cancers: a grand challenge in global health
Ginsburg, O., Bray, F., Coleman, M. P., Vanderpuye, V., Eniu, A., Kotha, S. R., Sarker, M., Huong, T. T., Allemani, C., Dvaladze, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31392-7 · Cited by 1,127
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3809 · Cited by 1,071
Whole-genome analysis informs breast cancer response to aromatase inhibition
Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., Van Tine, B. A., Hoog, J., Goiffon, R. J., Goldstein, T. C., et al. (2012) · Nature · doi:10.1038/nature11143 · Cited by 1,023
Smith, E. M. L., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N., et al. (2013) · JAMA · doi:10.1001/jama.2013.2813 · Cited by 1,014
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer
Poortmans, P. M., Collette, S., Kirkove, C., Van Limbergen, E., Budach, V., Struikmans, H., Collette, L., Fourquet, A., Maingon, P., Valli, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415369 · Cited by 1,005
Self-citationMagnetic resonance imaging of the breast: Recommendations from the EUSOMA working group
Sardanelli, F., Boetes, C., Borisch, B., Decker, T., Federico, M., Gilbert, F. J., Helbich, T., Heywang-Köbrunner, S. H., Kaiser, W. A., Kerin, M. J., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.015 · Cited by 992
Breast-Cancer Screening — Viewpoint of the IARC Working Group
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Benbrahim-Tallaa, L., Bouvard, V., Bianchini, F., & Straif, K. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1504363 · Cited by 962
Alcohol and Breast Cancer in Women: A Pooled Analysis of Cohort Studies
Smith-Warner, S. A., Spiegelman, D., Yaun, S.-S., van den Brandt, P. A., Folsom, A. R., Goldbohm, R. A., Graham, S., Holmberg, L., Howe, G. R., Marshall, J. R., et al. (1998) · JAMA · doi:10.1001/jama.279.7.535 · Cited by 941
Lucci, A., McCall, L. M., Beitsch, P. D., Whitworth, P. W., Reintgen, D. S., Blumencranz, P. W., Leitch, A. M., Saha, S., Hunt, K. K., & Giuliano, A. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4062 · Cited by 920
Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Picon‐Ruiz, M., Morata‐Tarifa, C., Valle‐Goffin, J. J., Friedman, E. R., & Slingerland, J. M. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21405 · Cited by 893
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890
Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S.-A., Pedrini, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00163-7 · Cited by 880
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Vaidya, J. S., Wenz, F., Bulsara, M., Tobias, J. S., Joseph, D. J., Keshtgar, M., Flyger, H. L., Massarut, S., Alvarado, M., Saunders, C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61950-9 · Cited by 831
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Veronesi, U., Orecchia, R., Maisonneuve, P., Viale, G., Rotmensz, N., Sangalli, C., Luini, A., Veronesi, P., Galimberti, V., Zurrida, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70497-2 · Cited by 767
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., Ellis, M., Shapira, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406281 · Cited by 753
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404037 · Cited by 749
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Clough, K. B., Kaufman, G. J., Nos, C., Buccimazza, I., & Sarfati, I. M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0792-y · Cited by 691
Gulati, G., Heck, S. L., Ree, A. H., Hoffmann, P., Schulz-Menger, J., Fagerland, M. W., Gravdehaug, B., von Knobelsdorff-Brenkenhoff, F., Bratland, Å., Storås, T. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw022 · Cited by 687
Bartelink, H., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., Jager, J., Schinagl, D., Oei, B., Rodenhuis, C., Horiot, J.-C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71156-8 · Cited by 685
Self-citationTailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803164 · Cited by 684
Breast Cancer Epidemiology, Prevention, and Screening
Winters, S., Martin, C., Murphy, D., & Shokar, N. K. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2017.07.002 · Cited by 667
Genomic Evolution of Breast Cancer Metastasis and Relapse
Yates, L. R., Knappskog, S., Wedge, D., Farmery, J. H. R., Gonzalez, S., Martincorena, I., Alexandrov, L. B., Van Loo, P., Haugland, H. K., Lilleng, P. K., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.005 · Cited by 665
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., Gelmon, K., Whelan, T., Strasser-Weippl, K., Rubin, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604700 · Cited by 644
Bray, F., Ferlay, J., Laversanne, M., Brewster, D. H., Gombe Mbalawa, C., Kohler, B., Piñeros, M., Steliarova‐Foucher, E., Swaminathan, R., Antoni, S., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29670 · Cited by 643
Contemporary Hormonal Contraception and the Risk of Breast Cancer
Mørch, L. S., Skovlund, C. W., Hannaford, P. C., Iversen, L., Fielding, S., & Lidegaard, Ø. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700732 · Cited by 641
Polgár, C., Limbergen, E. V., Pötter, R., Kovács, G., Polo, A., Lyczek, J., Hildebrandt, G., Niehoff, P., Guinot, J. L., Guedea, F., et al. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.01.014 · Cited by 633
Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 633
Is Breast Cancer the Same Disease in Asian and Western Countries?
Leong, S. P. L., Shen, Z., Liu, T., Agarwal, G., Tajima, T., Paik, N., Sandelin, K., Derossis, A., Cody, H., & Foulkes, W. D. (2010) · World Journal of Surgery · doi:10.1007/s00268-010-0683-1 · Cited by 633
Nelson, H. D., Fu, R., Cantor, A., Pappas, M., Daeges, M., & Humphrey, L. (2016) · Annals of Internal Medicine · doi:10.7326/m15-0969 · Cited by 611
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer
Couch, F. J., Shimelis, H., Hu, C., Hart, S. N., Polley, E. C., Na, J., Hallberg, E., Moore, R., Thomas, A., Lilyquist, J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0424 · Cited by 611
A new periareolar mammaplasty: The “round block” technique
Benelli, L. (1990) · Aesthetic Plastic Surgery · doi:10.1007/bf01578332 · Cited by 611
Correa, C., Harris, E. E., Leonardi, M. C., Smith, B. D., Taghian, A. G., Thompson, A. M., White, J., & Harris, J. R. (2017) · Practical Radiation Oncology · doi:10.1016/j.prro.2016.09.007 · Cited by 611
Badwe, R., Hawaldar, R., Nair, N., Kaushik, R., Parmar, V., Siddique, S., Budrukkar, A., Mittra, I., & Gupta, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00135-7 · Cited by 592
Mamounas, E. P., Anderson, S. J., Dignam, J. J., Bear, H. D., Julian, T. B., Geyer, C. E., Taghian, A., Wickerham, D. L., & Wolmark, N. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.8369 · Cited by 587
Martin, M., Holmes, F. A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S. K. L., Mansi, J., Barrios, C. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30717-9 · Cited by 585
Self-citationGlobal trends in breast cancer incidence and mortality 1973–1997
Althuis, M. D., Dozier, J. M., Anderson, W. F., Devesa, S. S., & Brinton, L. A. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyh414 · Cited by 564
Gnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., Wette, V., Balic, M., Haslbauer, F., Melbinger, E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60995-3 · Cited by 559
Self-citationBaselga, J., Im, S.-A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 533
Houssami, N., Macaskill, P., Luke Marinovich, M., & Morrow, M. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3480-5 · Cited by 532
Self-citationEstimation of the Number of Women Living with Metastatic Breast Cancer in the United States
Mariotto, A. B., Etzioni, R., Hurlbert, M., Penberthy, L., & Mayer, M. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0889 · Cited by 529
Genetics of breast cancer: a topic in evolution
Shiovitz, S., & Korde, L. A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv022 · Cited by 525
Moderate Alcohol Consumption During Adult Life, Drinking Patterns, and Breast Cancer Risk
Chen, W. Y., Rosner, B., Hankinson, S. E., Colditz, G. A., & Willett, W. C. (2011) · JAMA · doi:10.1001/jama.2011.1590 · Cited by 509
Singletary, K. W., & Gapstur, S. M. (2001) · JAMA · doi:10.1001/jama.286.17.2143 · Cited by 509
Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., Jackisch, C., Cameron, D., Weber, H. A., Heinzmann, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61094-6 · Cited by 497
Giuliano, A. E., Ballman, K., McCall, L., Beitsch, P., Whitworth, P. W., Blumencranz, P., Leitch, A. M., Saha, S., Morrow, M., & Hunt, K. K. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001863 · Cited by 497
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.11.012 · Cited by 495
Self-citationBRCA1 and its toolbox for the maintenance of genome integrity
Huen, M. S. Y., Sy, S. M. H., & Chen, J. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2831 · Cited by 490
Dawood, S., Merajver, S. D., Viens, P., Vermeulen, P. B., Swain, S. M., Buchholz, T. A., Dirix, L. Y., Levine, P. H., Lucci, A., Krishnamurthy, S., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq345 · Cited by 488
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
Korde, L. A., Zujewski, J. A., Kamin, L., Giordano, S., Domchek, S., Anderson, W. F., Bartlett, J. M. S., Gelmon, K., Nahleh, Z., Bergh, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5729 · Cited by 487
Self-citationLeukocyte composition of human breast cancer
Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104303108 · Cited by 479
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Penault-Llorca, F., Poortmans, P., Thompson, A., Zackrisson, S., & Cardoso, F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt284 · Cited by 479
Self-citationKim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
The molecular pathology of breast cancer progression
Bombonati, A., & Sgroi, D. C. (2011) · The Journal of Pathology · doi:10.1002/path.2808 · Cited by 455
MRI for breast cancer screening, diagnosis, and treatment
Morrow, M., Waters, J., & Morris, E. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61350-0 · Cited by 448
Spectrum of Breast Cancer in Asian Women
Agarwal, G., Pradeep, P. V., Aggarwal, V., Yip, C., & Cheung, P. S. Y. (2007) · World Journal of Surgery · doi:10.1007/s00268-005-0585-9 · Cited by 443
Dieci, M. V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., Pruneri, G., D’Alfonso, T. M., Demaria, S., Castaneda, C., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.003 · Cited by 433
Self-citationThorsen, L. B. J., Offersen, B. V., Danø, H., Berg, M., Jensen, I., Pedersen, A. N., Zimmermann, S. J., Brodersen, H.-J., Overgaard, M., & Overgaard, J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.6456 · Cited by 426
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Nelson, H. D., Pappas, M., Cantor, A., Griffin, J., Daeges, M., & Humphrey, L. (2016) · Annals of Internal Medicine · doi:10.7326/m15-0970 · Cited by 410
Cardoso, F., Bartlett, J. M. S., Slaets, L., van Deurzen, C. H. M., van Leeuwen-Stok, E., Porter, P., Linderholm, B., Hedenfalk, I., Schröder, C., Martens, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx651 · Cited by 405
Self-citationGray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., Taylor, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33137-4 · Cited by 400
Self-citationPaluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., & Senkus, E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw327 · Cited by 399
Self-citationBodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Wang, S.-L., Fang, H., Song, Y.-W., Wang, W.-H., Hu, C., Liu, Y.-P., Jin, J., Liu, X.-F., Yu, Z.-H., Ren, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30813-1 · Cited by 396
Male breast cancer: a disease distinct from female breast cancer
Gucalp, A., Traina, T. A., Eisner, J. R., Parker, J. S., Selitsky, S. R., Park, B. H., Elias, A. D., Baskin-Bey, E. S., & Cardoso, F. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4921-9 · Cited by 392
Self-citationMunster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391
Morrow, M., Van Zee, K. J., Solin, L. J., Houssami, N., Chavez-MacGregor, M., Harris, J. R., Horton, J., Hwang, S., Johnson, P. L., Marinovich, M. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.3573 · Cited by 386
Self-citationHahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A., Denkert, C., Fasching, P. A., Blohmer, J. U., Jackisch, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1007 · Cited by 384
Marinovich, M. L., Houssami, N., Macaskill, P., Sardanelli, F., Irwig, L., Mamounas, E. P., von Minckwitz, G., Brennan, M. E., & Ciatto, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs528 · Cited by 382
Self-citationBareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., & Sotiriou, C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy024 · Cited by 382
Melnikow, J., Fenton, J. J., Whitlock, E. P., Miglioretti, D. L., Weyrich, M. S., Thompson, J. H., & Shah, K. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1789 · Cited by 376
Ellis, M. J., Suman, V. J., Hoog, J., Goncalves, R., Sanati, S., Creighton, C. J., DeSchryver, K., Crouch, E., Brink, A., Watson, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.4406 · Cited by 366
Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments
Gillespie, T. C., Sayegh, H. E., Brunelle, C. L., Daniell, K. M., & Taghian, A. G. (2018) · Gland Surgery · doi:10.21037/gs.2017.11.04 · Cited by 361
Tamura, K., Tsurutani, J., Takahashi, S., Iwata, H., Krop, I. E., Redfern, C., Sagara, Y., Doi, T., Park, H., Murthy, R. K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30097-x · Cited by 352
Breast cancer precursors revisited: molecular features and progression pathways
Lopez‐Garcia, M. A., Geyer, F. C., Lacroix‐Triki, M., Marchió, C., & Reis‐Filho, J. S. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03568.x · Cited by 347
Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Gonzalez-Angulo, A. M., Krop, I., Levinson, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0948 · Cited by 343
Pivot, X., Romieu, G., Debled, M., Pierga, J.-Y., Kerbrat, P., Bachelot, T., Lortholary, A., Espié, M., Fumoleau, P., Serin, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70225-0 · Cited by 337
Houssami, N., Ciatto, S., Turner, R. M., Cody, H. S., & Macaskill, P. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31821f1564 · Cited by 332
Self-citationGenomic Characterization of Primary Invasive Lobular Breast Cancer
Desmedt, C., Zoppoli, G., Gundem, G., Pruneri, G., Larsimont, D., Fornili, M., Fumagalli, D., Brown, D., Rothé, F., Vincent, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0334 · Cited by 318
Family history and risk of breast cancer: an analysis accounting for family structure
Brewer, H. R., Jones, M. E., Schoemaker, M. J., Ashworth, A., & Swerdlow, A. J. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4325-2 · Cited by 316
Krop, I., Ismaila, N., Andre, F., Bast, R. C., Barlow, W., Collyar, D. E., Hammond, M. E., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.0472 · Cited by 315
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu544 · Cited by 312
Self-citationChow, E., van der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S. Y., Brundage, M. D., Nabid, A., Tissing-Tan, C. J. A., Oei, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70556-4 · Cited by 306
Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E., Jacobs, S. A., Robert, N. J., Hopkins, J. O., O'Shaughnessy, J. A., Dang, C. T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4147 · Cited by 294
Aurilio, G., Disalvatore, D., Pruneri, G., Bagnardi, V., Viale, G., Curigliano, G., Adamoli, L., Munzone, E., Sciandivasci, A., De Vita, F., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.10.004 · Cited by 292
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015
Daly, M. B., Pilarski, R., Axilbund, J. E., Berry, M., Buys, S. S., Crawford, B., Farmer, M., Friedman, S., Garber, J. E., Khan, S., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0018 · Cited by 292
Earl, H. M., Hiller, L., Vallier, A.-L., Loi, S., McAdam, K., Hughes-Davies, L., Harnett, A. N., Ah-See, M.-L., Simcock, R., Rea, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30650-6 · Cited by 286
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Gobbini, E., Ezzalfani, M., Dieras, V., Bachelot, T., Brain, E., Debled, M., Jacot, W., Mouret-Reynier, M. A., Goncalves, A., Dalenc, F., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.015 · Cited by 276
The prognostic significance of lymphovascular invasion in invasive breast carcinoma
Rakha, E. A., Martin, S., Lee, A. H. S., Morgan, D., Pharoah, P. D. P., Hodi, Z., MacMillan, D., & Ellis, I. O. (2012) · Cancer · doi:10.1002/cncr.26711 · Cited by 271
McGuire, S. E., Gonzalez-Angulo, A. M., Huang, E. H., Tucker, S. L., Kau, S.-W. C., Yu, T.-K., Strom, E. A., Oh, J. L., Woodward, W. A., Tereffe, W., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.01.023 · Cited by 257
Pregnancy and the risk of breast cancer
Britt, K., Ashworth, A., & Smalley, M. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0137 · Cited by 254
Candido dos Reis, F. J., Wishart, G. C., Dicks, E. M., Greenberg, D., Rashbass, J., Schmidt, M. K., van den Broek, A. J., Ellis, I. O., Green, A., Rakha, E., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0852-3 · Cited by 252
Physical and Psychosocial Recovery in the Year After Primary Treatment of Breast Cancer
Ganz, P. A., Kwan, L., Stanton, A. L., Bower, J. E., & Belin, T. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8043 · Cited by 251
Marinovich, M. L., Hunter, K. E., Macaskill, P., & Houssami, N. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy121 · Cited by 249
Self-citationElkins, G., Marcus, J., Stearns, V., Perfect, M., Rajab, M. H., Ruud, C., Palamara, L., & Keith, T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6389 · Cited by 245
Offersen, B. V., Boersma, L. J., Kirkove, C., Hol, S., Aznar, M. C., Sola, A. B., Kirova, Y. M., Pignol, J.-P., Remouchamps, V., Verhoeven, K., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.12.027 · Cited by 243
Self-citationPartridge, A. H., Rumble, R. B., Carey, L. A., Come, S. E., Davidson, N. E., Di Leo, A., Gralow, J., Hortobagyi, G. N., Moy, B., Yee, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7479 · Cited by 240
Gnant, M., Pfeiler, G., Steger, G. G., Egle, D., Greil, R., Fitzal, F., Wette, V., Balic, M., Haslbauer, F., Melbinger-Zeinitzer, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30862-3 · Cited by 239
Self-citationBevans, M., Ross, A., & Cella, D. (2014) · Nursing Outlook · doi:10.1016/j.outlook.2014.05.009 · Cited by 238
BRCA in breast cancer: ESMO Clinical Practice Guidelines
Balmaña, J., Díez, O., Rubio, I. T., & Cardoso, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr373 · Cited by 230
Self-citationMiles, D. W., Diéras, V., Cortés, J., Duenne, A.-A., Yi, J., & O'Shaughnessy, J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt276 · Cited by 228
Blamey, R. W., Bates, T., Chetty, U., Duffy, S. W., Ellis, I. O., George, D., Mallon, E., Mitchell, M. J., Monypenny, I., Morgan, D. A. L., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.031 · Cited by 222
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy
King, T. A., & Morrow, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.63 · Cited by 215
Morrow, M., Van Zee, K. J., Solin, L. J., Houssami, N., Chavez-MacGregor, M., Harris, J. R., Horton, J., Hwang, S., Johnson, P. L., Marinovich, M. L., et al. (2016) · Practical Radiation Oncology · doi:10.1016/j.prro.2016.06.011 · Cited by 215
Self-citationFitzal, F., Bjelic-Radisic, V., Knauer, M., Steger, G., Hubalek, M., Balic, M., Singer, C., Bartsch, R., Schrenk, P., Soelkner, L., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002771 · Cited by 214
Self-citationEpidemiology — identifying the causes and preventability of cancer?
Colditz, G. A., Sellers, T. A., & Trapido, E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1784 · Cited by 209
Prognostic models for breast cancer: a systematic review
Phung, M. T., Tin Tin, S., & Elwood, J. M. (2019) · BMC Cancer · doi:10.1186/s12885-019-5442-6 · Cited by 209
Aromatase inhibitor-induced arthralgia: a review
Niravath, P. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt037 · Cited by 207
Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods
Carter, J. L., Coletti, R. J., & Harris, R. P. (2015) · BMJ · doi:10.1136/bmj.g7773 · Cited by 207
Del Mastro, L., De Placido, S., Bruzzi, P., De Laurentiis, M., Boni, C., Cavazzini, G., Durando, A., Turletti, A., Nisticò, C., Valle, E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62048-1 · Cited by 206
Klarenbach, S., Sims-Jones, N., Lewin, G., Singh, H., Thériault, G., Tonelli, M., Doull, M., Courage, S., Garcia, A. J., & Thombs, B. D. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180463 · Cited by 205
Haloua, M. H., Krekel, N. M. A., Winters, H. A. H., Rietveld, D. H. F., Meijer, S., Bloemers, F. W., & van den Tol, M. P. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182888782 · Cited by 201
Standardized synoptic cancer pathology reporting: A population‐based approach
Srigley, J. R., McGowan, T., MacLean, A., Raby, M., Ross, J., Kramer, S., & Sawka, C. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21282 · Cited by 200
Marinovich, M. L., Sardanelli, F., Ciatto, S., Mamounas, E., Brennan, M., Macaskill, P., Irwig, L., von Minckwitz, G., & Houssami, N. (2012) · The Breast · doi:10.1016/j.breast.2012.07.006 · Cited by 198
Self-citationDefining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Cheang, M. C. U., Martin, M., Nielsen, T. O., Prat, A., Voduc, D., Rodriguez-Lescure, A., Ruiz, A., Chia, S., Shepherd, L., Ruiz-Borrego, M., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0372 · Cited by 194
Surgical Margins in Lumpectomy for Breast Cancer — Bigger Is Not Better
Morrow, M., Harris, J. R., & Schnitt, S. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmsb1202521 · Cited by 189
Balic, M., Thomssen, C., Würstlein, R., Gnant, M., & Harbeck, N. (2019) · Breast Care · doi:10.1159/000499931 · Cited by 172
Self-citationEstrogen receptors outside the nucleus in breast cancer
Levin, E. R., & Pietras, R. J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9618-4 · Cited by 168
Razvi, Y., Chan, S., McFarlane, T., McKenzie, E., Zaki, P., DeAngelis, C., Pidduck, W., Bushehri, A., Chow, E., & Jerzak, K. J. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-018-4464-y · Cited by 167
Genomic landscape of adenoid cystic carcinoma of the breast
Martelotto, L. G., Filippo, M. R. D., Ng, C. K. Y., Natrajan, R., Fuhrmann, L., Cyrta, J., Piscuoglio, S., Wen, H., Lim, R. S., Shen, R., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4573 · Cited by 167
Wendt, C., & Margolin, S. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1529428 · Cited by 164
Bhoo‐Pathy, N., Yip, C. H., Taib, N. A. M., Hartman, M., Saxena, N., Iau, P. C. T., Bulgiba, A. M., Lee, S. C., Lim, S. E., Wong, J. E. L., et al. (2011) · The Breast · doi:10.1016/j.breast.2011.01.015 · Cited by 163
Health-related quality of life in Asian patients with breast cancer: a systematic review
Ho, P. J., Gernaat, S. A. M., Hartman, M., & Verkooijen, H. M. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020512 · Cited by 160
Vila, J., Gandini, S., & Gentilini, O. (2015) · The Breast · doi:10.1016/j.breast.2015.02.002 · Cited by 159
Osman, S. O. S., Hol, S., Poortmans, P. M., & Essers, M. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.04.004 · Cited by 159
Self-citation
Research works printed but not linked: 11
- Hossain, M. S., Ferdous, S. & Karim-Kos, H. E. Breast cancer in South. Asia: a Bangladeshi perspective. Cancer Epidemiol. 38, 465–470 (2014).
- Li, C. I., Malone, K. E. & Daling, J. R. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol. Biomark. Prev. 11, 601–607 (2002).
- World Heath Organisation. WHO Classification of Tumours of the Breast, Fourth Edition. (World Health Organization, 2012).
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771–784 (2011). · DOI · Paper page
- Dare, A. J. et al. Surgical Services for Cancer Care. in Cancer: Disease Control Priorities, Third Edition (Volume 3) (eds. Gelband, H., Jha, P., Sankaranarayanan, R. & Horton, S.) (The International Bank for Reconstruction and Development/The World Bank, 2015).
- Sologuren, I., Rodríguez-Gallego, C. & Lara, P. C. Immune effects of high dose radiation treatment: implications of ionizing radiation on the development of bystander and abscopal effects. Transl Cancer Res. 3, 18-31–31 (2014).
- Morgan, S., Caudrelier, J.-M. & Clemons, M. Radiotherapy to the primary tumor is associated with improved survival in stage IV breast cancer [abstract]. SABCS P4, 16–06 (2012).
- Hou, S., Huh, B., Kim, H. K., Kim, K.-H. & Abdi, S. Treatment of chemotherapy-induced peripheral neuropathy: systematic review and recommendations. Pain Physician 21, 571–592 (2018).
- Desmedt, C. et al. Unraveling lobular breast cancer progression and endocrine resistance mechanisms through genomic and immune characterization of matched primary and metastatic samples [abstract]. SABCS GS1–06 (2018).
- Cortes, J., Crown, J. & Awada, A. Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC) [abstract]. Eur. Cancer Congr. 51 (Suppl. 3), 1802 (2015).
- Hoadley, K. A., Andre, F., Ellis, M. J. & Perou, C. M. Breast cancer intrinsic subtypes (Poster). Nat. Rev. Clin. Oncol. https://www.nature.com/documents/nrclinonc_posters_breastcancer.pdf (2014).
Cited by
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
Self-citationPyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“Few (88) of these patients were treated in the CLEOPATRA trial and all with a trastuzumabfree interval >12 months.”
BackgroundSelf-citationTrastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175
Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083
Self-citation
Metadata
- Authors
- Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F.
- Affiliations
- LMU Klinikum (DE)
- Medical University of Vienna (AT)
- The University of Sydney (AU)
- Université Paris Sciences et Lettres (FR)
- Mayo Clinic (US)
- University of Hong Kong (HK)
- Corresponding author
- Harbeck, Nadia
- Venue
- Nature Reviews Disease Primers
- Published
- 2019-09-23
- Volume
- 5
- Issue
- 1
- Pages
- 66-66
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4211005384
- Cited by
- 3,024
- References
- 324
- Citations by year
- 2026: 344 · 2025: 500 · 2024: 536 · 2023: 510 · 2022: 503 · 2021: 425 · 2020: 195 · 2019: 8
- FWCI
- 27.21
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Disease Primers (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- The Sydney eScholarship Repository (The University of Sydney) (submittedVersion)
- The Sydney eScholarship Repository (The University of Sydney) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (KL2TR002379)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- breast cancer, HER2, oestrogen receptor, progesterone receptor, BRCA mutations, molecular subtypes, endocrine therapy, chemotherapy, HER2-targeted therapy, PARP inhibitors, immunotherapy, locoregional therapy, systemic therapy, treatment de-escalation, treatment escalation, personalized treatment, access to cancer care
- MeSH terms
- Adult, Breast Neoplasms, Female, Humans, Biomarkers, Tumor, Survivors, Erb-b2 Receptor Tyrosine Kinases, BRCA2 Protein, Ubiquitin-Protein Ligases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.